Clinical Trial Search

Primary: Day 22 Minimal Residual Disease (MRD) Measured by Flow Cytometry — 42; 57; 79; 64 Participants — p=0.035

Primary: Number of Participants With Daily Medication Compliance — 24 Participants

Primary: Progression-free Survival (PFS) Defined as the Time From Patient Recruitment to Biochemical Progression Based on Doubling of Prostate Specific Antigen (PSA) Velocity or…

Primary: Blood Alcohol Level — 0 Participants

Primary: Percentage of Patients With ≥50% Seizure Reduction During the Maintenance Period Compared With Seizure Frequency Before Initiation of Perampanel

Primary: Change in Leucine Disposal Rate (LDR) — -0.011; 0.005; 0.001 mg/kg/min — p=0.37

Primary: Number of Subjects With Vaccine Response to Meningococcal Antigens — 472; 148; 625; 204 Participants

Primary: Days to Reach Full Enteral Feedings and Days on Study Oil. — 20.00; 16.21; 34.00; 33.71 days — p=0.07

Primary: Change From Baseline in 24 Hour UGE on Day 7 — -0.46; 64.63; 80.73; 97.64 gram per 24 hours (g/24 h) — p=<0.0001

Primary: 3-Month Progression-Free Survival (PFS3) — 0 Participants

Primary: Change in Urinary Nerve Growth Factor (pg/mL) at Baseline Compared to Post Dose Exposure at Mo.3/Wk12 — -10.9 pg/ml

Primary: Change From Baseline in Forced Expiratory Volume (FEV1) Area Under the Curve (AUC) 0-24h — 0.1846; 0.2028 Liters — p=0.415

Primary: Procedure Success — 121; 5 Participants

Primary: Phase 1: Number of Subjects With Treatment-Emergent Adverse Events (TEAE) of Grade Greater Than or Equal to (≥) 3 in Severity — 26; 12; 6; 1 Participants

Primary: Change From Baseline in Lung Clearance Index (LCI) — -0.03; -0.16 Days — p=0.130